Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 18 |
| Active Pipeline (Recruiting Now) | 9 (8) |
| Completed vs Stopped Early | 9 / 0 (0.0%) |
| Median Closed Actual Enrollment | 53 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Fujian Cancer Hospital | Fuzhou, Fujian | 6 |
| Peking Union Medical College Hospital | Beijing, Beijing Municipality | 6 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Wuhan, Hubei | 6 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT05686642 | Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke | Phase II | RECRUITING |
| NCT06434597 | A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients. | Phase II | RECRUITING |
| NCT05872347 | Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases. | Phase II | RECRUITING |
| NCT05860465 | Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer | Phase II/III | RECRUITING |
| NCT05744687 | Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer | Phase II/III | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the Shanghai Pharmaceuticals Holding Co Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.